-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to IDF data, the number of adults with diabetes in the world has reached 463 million in 2019 and is expected to reach 700 million by 2045
.
In 2019, there were 116 million adults with diabetes in China, ranking first in the world, and it will reach 140 million by 2030
Data source: Mid-term annual reports of various companies
The five major pharmaceutical companies in the first half of 2021 had 24 diabetes drugs with a sales volume of over 100 million U.
S.
dollars.
They were divided into three categories: GLP-1, oral drugs, and insulin, with sales totaling 20.
128 billion U.
S.
dollars, of which there were 5 GLP-1.
Ozempic, Victoza, Rybelsus, Trulicity, and Bydureon have sales totaling US$6.
901 billion.
There are 6 oral products, namely Jardiance, Trajenta, Januvia, Janumet, Farxiga, and Onglyza, with sales totaling US$4.
964 billion; there are 13 insulin models.
They are NovoRapid, NovoMix, Tresiba, Levemir, Xultophy, Ryzodeg, Fiasp, Humalog, Humulin, Basaglar, Lantus, Toujeo, Soliqua, with sales totaling US$8.
263 billion
.
By comparison, we can find that insulin drugs account for the largest proportion, reaching 54%, but only 41% of total sales, while GLP-1 and oral drugs, which account for a smaller proportion, account for 59% of sales.
This shows that new drugs are increasingly favored by the market
.
In particular, GLP-1 drugs, which account for 21% of the three drugs, have the highest sales, accounting for 34% of total sales
Novo Nordisk
Novo Nordisk Novo Nordisk is headquartered in Copenhagen, Denmark, and its history goes back to the Nordisk Insulin Laboratory founded in 1923 and the Novo Therapeutics Laboratory established in 1925.
It originated from the development of the two laboratories of Nordisk, Novo Nordisk merged to form Novo Nordisk in 1986 and became the world's largest diabetes pharmaceutical company
.
Novo Nordisk's diabetes business revenue in the first half of 2021 reached 8.
Eli Lilly
Eli Lilly Eli Lilly was formally established in Indiana, USA in 1901, with a history going back to the pharmaceutical manufacturing business established by Colonel Eli Lilly in 1876
.
Eli Lilly, the world’s second-largest diabetes pharmaceutical company, has revenues of US$6.
Balanced development of Merck
Balanced development of Merck The headquarters of Merck is in Kenilworth, New Jersey, USA.
Its history can be traced back to 1891.
When the German Merck entered the United States to expand the market, in 1953, Merck and Saud Corporation merged, called Merck in North America, and other regions outside North America.
Called Merck
.
Merck’s diabetes business revenue in the first half of 2021 was US$2.
Slightly monotonous Sanofi
Slightly monotonous Sanofi Sanofi is headquartered in France, and the company's history dates back to 1982
.
Sanofi’s diabetes business revenue in the first half of 2021 was US$2.
Deeply plowing China AstraZeneca
Deeply plowing China AstraZeneca AstraZeneca is headquartered in Cambridge, England.
It was formed by the merger of the former Swedish Astra Company and the former British Zeleca Company in 1999
.
AstraZeneca’s diabetes business revenue in the first half of 2021 was US$1.
